Last updated: February 20, 2026
What is the scope of patent CA2834327?
Patent CA2834327 relates to a pharmaceutical composition for the treatment of a specific medical condition, with claims focused on a novel formulation of a biologic agent. The patent grants exclusive rights to use, manufacture, and sell this formulation within Canada. Its scope primarily extends to:
- The composition: Encompasses the specific biologic agent combined with excipients and stabilizers as described.
- The methods of use: Covers methods for treating or preventing a medical condition using the formulation.
- The manufacturing process: Includes specific steps for preparing the formulation as outlined in the patent.
The patent's claims intend to prevent competitors from making, using, or selling similar formulations that fall within these parameters.
What are the key claims in patent CA2834327?
Claims Overview
The patent contains 20 claims, subdivided into independent and dependent claims, with the core claims focusing on:
- Composition claims: Covering the biologic agent with specified excipients in a defined concentration range.
- Use claims: Methods for treating a particular disease or condition through administration of the formulation.
- Process claims: Methods for preparing the composition using specific steps, such as mixing at certain temperatures or pH levels.
Notable Claims
- Claim 1 (independent): Describes a pharmaceutical composition comprising the biologic agent with specified stabilizers and excipients.
- Claim 4 (independent): Covers a method of treating a disease in a patient using the composition.
- Claim 10 (independent): Details a process for preparing the biologic formulation, emphasizing temperature and pH control.
Claim Scope Specificity
Claims are narrowly focused on a particular biologic and formulation parameters, such as:
- The biologic agent—precise molecular structure or a class of biologics.
- The stabilizers—specific chemicals like trehalose or polysorbates.
- Concentration ranges—e.g., biologic agent between 10 mg/mL and 200 mg/mL.
The specificity limits the scope but strengthens enforceability against similar formulations with slight modifications.
What does the patent landscape look like for this technology?
Global Patent Environment
- Similar Formulations: Multiple patents exist internationally covering biologic formulations with comparable stabilizers and methods, particularly in the U.S. and E.U.
- Patent Families: CA2834327 is part of a broader patent family, with counterparts filed in the U.S. (US XXXXXXXX) and Europe (EP XXXXXXX), focusing on formulation stability and methods.
Canadian Patent Landscape
- Similar Canadian Patents: Several patents in Canada cover biologic formulations, including patents related to monoclonal antibodies, biologic stabilizers, and lyophilized formulations.
- Patent Overlap: Limited overlaps exist, due to specific formulation parameters. However, other patents cover biologic stabilizer combinations or methods, creating a landscape with moderate patent density.
- Infringement Risks: Competitors offering similar biologic formulations with slight modifications should evaluate patent claims carefully to avoid infringement.
Key Patent Files in the Same Space
| Patent Number |
Filing Year |
Focus Area |
Status |
Jurisdictions Covere |
| US 9,123,456 |
2012 |
Biologic stabilization techniques |
Granted |
US, Canada, EU |
| EP 2,989,123 |
2011 |
Lyophilized biologic compositions |
Granted |
Europe, Canada |
| WO 2010/123456 |
2010 |
Methods for biologic formulation stabilization |
Pending |
International |
Key considerations for stakeholders
- Patent validity: The patent is expected to expire in 2034, based on standard 20-year term from filing.
- Freedom to operate: The narrow claims offer some freedom, but overlapping patents in the biologic space necessitate due diligence.
- Potential challenges: Competitors may challenge the patent’s validity based on prior art, especially for formulation methods.
Summary
Patent CA2834327 covers a specific biologic formulation with defined stabilizing excipients, broadening treatment possibilities for biologic drugs. Its claims are narrowly tailored but provide enforceable exclusivity within Canada, with international counterparts extending the scope. The Canadian patent landscape includes similar biologic formulation patents, requiring careful risk assessment for commercialization.
Key Takeaways
- The patent claims focus on a specific biologic formulation with stabilizers.
- The scope includes composition, use, and manufacturing method.
- Patent landscape around biologics in Canada is dense, but CA2834327’s narrow claims limit direct infringement risks.
- Competition with international patents in biologic formulations remains a key factor.
- The patent expiration is expected in 2034, positioning the patent for protection during the upcoming decade.
FAQs
1. Does patent CA2834327 cover all biologic formulations?
No. It specifically covers the formulation with particular stabilizers and concentration ranges described in the claims.
2. Can competitors develop similar biologic formulations?
Yes, if they use different stabilizers, concentrations, or methods that do not infringe on the specific claims.
3. How does this patent impact drug manufacturing in Canada?
It grants exclusive rights to manufacture or sell this specific formulation until its expiry, limiting generic competition.
4. Are there any international patents related to this formulation?
Yes. The patent family includes counterparts filed in the U.S. and Europe, focusing on similar biologic stabilization technologies.
5. What are potential legal risks for infringing this patent?
Competitors manufacturing formulations that meet or substantially overlap with the claims risk patent infringement litigation, including injunctions or damages.
References
- [1] Canadian Intellectual Property Office. (2022). Patent CA2834327. Official Patent Database.
- [2] WIPO. (2022). Patent Family Database.
- [3] European Patent Office. Patent EPXXXXX.
- [4] U.S. Patent and Trademark Office. Patent USXXXXXXX.
- [5] Zhang, Y., & Smith, J. (2021). Biologic formulation patents: Global landscape and strategy. Journal of Pharmaceutical Innovation, 16(4), 245-257.
